Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma

doi:10.1021/mp500755j

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma
	Cao, Haiqiang 1,2; Wang, Yixin 1,2,3; He, Xinyu 1,2; Zhang, Zhiwen1,2 ; Yin, Qi1,2 ; Chen, Yi1,2 ; Yu, Haijun1,2 ; Huang, Yongzhuo1,2 ; Chen, Lingli1,2 ; Xu, Minghua1,2
刊名	MOLECULAR PHARMACEUTICS
	2015-03
卷号	12 期号:3 页码:922-931
关键词	sorafenib curcumin nanoparticles codelivery hepatocellular carcinoma
ISSN号	1543-8384
DOI	10.1021/mp500755j
文献子类	Article
英文摘要	Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Herein, we first reported the codelivery of sorafenib and curcumin by directed self-assembled nanoparticles (SCN) to enhance the therapeutic effect on HCC. SCN was formed by employing the hydrophobic interactions among the lipophilic structure in sorafenib, curcumin, and similar hydrophobic segments of polyethylene glycol derivative of vitamin E succinate (PEG-VES), which comprised uniform spherical particles with particle size of 84.97 +/- 6.03 nm. SCN presented superior effects over sorafenib, curcumin, and their physical mixture (Sora + Cur) on enhancing in vitro cytotoxicity and cell apoptosis in BEL-7402 cells and Hep G2 cells, and antiangiogenesis activities in tube formation and microvessel formation from aortic rings. Moreover, the tissue concentration of sorafenib and curcumin in gastrointestinal tract and major organs were significantly improved after their coassembly into SCN. In particular, in BEL-7402 cells induced tumor xenograft, SCN treatment displayed the obviously enhanced inhibitory effect on tumor progression over free drug monotherapy or their physical mixture, with significantly increased antiproliferation and antiangiogenesis capability. Thereby, the codelivered nanoassemblies of sorafenib and curcumin provided a promising strategy to enhance the combinational therapy of HCC.
资助项目	National Basic Research Program of China[2015CB932103] ; National Basic Research Program of China[2012CB932502] ; National Natural Science Foundation of China[81270047] ; National Natural Science Foundation of China[81373359]
WOS关键词	BREAST-CANCER ; MULTIDRUG-RESISTANCE ; ORAL DELIVERY ; TUMOR-GROWTH ; CO-DELIVERY ; COMBINATION ; DOXORUBICIN ; METASTASIS ; INHIBITION ; PACLITAXEL
WOS研究方向	Research & Experimental Medicine ; Pharmacology & Pharmacy
语种	英语
出版者	AMER CHEMICAL SOC
WOS记录号	WOS:000350390900025
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/276624]
专题	药物制剂研究中心中科院受体结构与功能重点实验室新药研究国家重点实验室
通讯作者	Zhang, Zhiwen
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China; 3.Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China
推荐引用方式 GB/T 7714	Cao, Haiqiang,Wang, Yixin,He, Xinyu,et al. Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma[J]. MOLECULAR PHARMACEUTICS,2015,12(3):922-931.
APA	Cao, Haiqiang.,Wang, Yixin.,He, Xinyu.,Zhang, Zhiwen.,Yin, Qi.,...&Li, Yaping.(2015).Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma.MOLECULAR PHARMACEUTICS,12(3),922-931.
MLA	Cao, Haiqiang,et al."Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma".MOLECULAR PHARMACEUTICS 12.3(2015):922-931.